Forum Menu - Click/Swipe to open
 
Top Members

Nano Robots and DNA

You have contributed 0.0% of this topic

Thread Tools
Appreciate
Topic Appreciation
abuzayd2k
Rank Image
Offline
Unspecified
767
Brother
1,007
#16 [Permalink] Posted on 23rd January 2021 07:18
abu mohammed wrote:
View original post

That's a good thing, ain't it? Right now we are unworthy gentiles this will make us more kosher.
report post quote code quick quote reply
back to top
Rank Image
abu mohammed's avatar
London
23,885
Brother
9,077
abu mohammed's avatar
#17 [Permalink] Posted on 18th November 2021 10:05
abu mohammed wrote:
View original post

UK to trial skin patch vaccine

www.theguardian.com/society/2021/nov/15/uk-firm-to-trial-...
An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.

Emergex obtains approval to commence Phase I trial of Covid-19 vaccine
16 Nov 2021
Subject dosing in the trial to assess safety and tolerability of the vaccine will begin in January next year.
www.clinicaltrialsarena.com/news/emergex-trial-covid-vacc...

Emergex Vaccines has obtained regulatory approvals to commence the Phase I clinical trial of its Covid-19 vaccine candidate.

The double-blind, randomised, comparator-controlled trial will analyse the safety and tolerability of high and low doses of the vaccine.

To be conducted by the University of Lausanne, Switzerland Center for Primary Care and Public Health professor Blaise Genton, the trial will enrol a total of 13 subjects into two groups.

The company expects to dose the first subject with the first dose of the vaccine in January 2022.

Apart from safety and tolerability, the trial will offer information on CD8+ T-Cell-facilitated immune responses as a measure of protection against SARS-CoV-2 infection.

Emergex Vaccines chief commercial officer Robin Cohen said: “Our T Cell priming vaccines may offer significant benefits over current Covid-19 vaccines, including longer-lasting immunity and broader protection against new variants.

“We are proud to announce the initiation of this trial and look forward to gathering data to support the development of this important next-generation vaccine.”

The company is currently carrying out another Phase I trial of its dengue vaccine candidate in Switzerland.
report post quote code quick quote reply
back to top